Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization studyOriginal paper
What was studied?
This study asked whether gut bacteria causally influence six diabetes complications: hypoglycemia, ketoacidosis, nephropathy, neuropathy, retinopathy, and Charcot's foot. The authors used two-sample Mendelian randomization. This method uses genetic variants (single-nucleotide polymorphisms) as instruments to infer causation and reduce confounding. Inverse variance weighted analysis was the primary method. Inverse MR tested reverse effects, and multivariate MR adjusted for traditional risk factors.
Who was studied?
The analysis used genome-wide summary data, not new patients, all from people of European ancestry. Gut microbiota data came from the MiBioGen consortium (18,340 participants across 24 cohorts) as discovery, with the Dutch Microbiome Project (7,738 participants) for replication. Complication data came from FinnGen (up to 377,277 samples). Case counts ranged from 473 for Charcot's foot to 7,841 for ketoacidosis. In total 196 bacterial taxa were tested.
What were the most important findings?
After multiple-testing correction, the Bacteroidia class and Bacteroidales order were positively linked to diabetic hypoglycemia (OR 1.3541, 95% CI 1.1346-1.6160, P 0.0008). The Verrucomicrobiae class and Verrucomicrobiales order were positively linked to diabetic nephropathy (OR about 1.40, 95% CI 1.1336-1.7319, P 0.0018). Across all six complications, 65 causal associations emerged (4 strong, 61 suggestive). Reverse MR found the complications did not alter these taxa. Multivariate MR kept results stable after adjusting for alcohol, LDL, triglycerides, and smoking.
What are the greatest implications of this study?
The findings offer genetic evidence that specific gut taxa may causally shape diabetes complications, pointing toward microbiome-based prevention. Because the method limits confounding and reverse causation, the associations are more robust than typical observational reports. The authors suggest possible targets for dietary therapy, probiotics, engineered microbes, and fecal transplantation. However, all data were European, no subgroup analysis by age or sex was possible, and suggestive links need further study.